HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal.

Abstract
Elevation of the neuropeptide corticotropin-releasing factor (CRF) in the brain is associated with a reduction of food intake and body weight gain in normal and obese animals. A protein that binds CRF and the related peptide, urocortin, with high affinity, CRF-binding protein (CRF-BP), may play a role in energy homeostasis by inactivating members of this peptide family in ingestive and metabolic regulatory brain regions. Intracerebroventricular administration in rats of the high-affinity CRF-BP ligand inhibitor, rat/human CRF (6-33), which dissociates CRF or urocortin from CRF-BP and increases endogenous brain levels of "free" CRF or urocortin significantly blunted exaggerated weight gain in Zucker obese subjects and in animals withdrawn from chronic nicotine. Chronic administration of CRF suppressed weight gain nonselectively by 60% in both Zucker obese and lean control rats, whereas CRF-BP ligand inhibitor treatment significantly reduced weight gain in obese subjects, without altering weight gain in lean control subjects. Nicotine abstinent subjects, but not nicotine-naive controls, experienced a 35% appetite suppression and a 25% weight gain reduction following acute and chronic administration, respectively, of CRF-BP ligand inhibitor. In marked contrast to the effects of a CRF-receptor agonist, the CRF-BP ligand inhibitor did not stimulate adrenocorticotropic hormone secretion or elevate heart rate and blood pressure. These results provide support for the hypothesis that the CRF-BP may function within the brain to limit selected actions of CRF and/or urocortin. Furthermore, CRF-BP may represent a novel and functionally selective target for the symptomatic treatment of excessive weight gain associated with obesity of multiple etiology.
AuthorsS C Heinrichs, J Lapsansky, D P Behan, R K Chan, P E Sawchenko, M Lorang, N Ling, W W Vale, E B De Souza
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 93 Issue 26 Pg. 15475-80 (Dec 24 1996) ISSN: 0027-8424 [Print] United States
PMID8986836 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Carrier Proteins
  • Recombinant Fusion Proteins
  • corticotropin releasing factor-binding protein
  • Nicotine
  • Corticotropin-Releasing Hormone
Topics
  • Animals
  • Carrier Proteins (antagonists & inhibitors)
  • Cerebral Ventricles (drug effects, physiology)
  • Corticotropin-Releasing Hormone (pharmacology, physiology)
  • Feeding Behavior (drug effects)
  • Humans
  • Infusions, Parenteral
  • Injections, Intraventricular
  • Male
  • Nicotine (pharmacology)
  • Obesity (genetics, prevention & control)
  • Rats
  • Rats, Zucker
  • Recombinant Fusion Proteins (pharmacology)
  • Substance Withdrawal Syndrome
  • Weight Gain (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: